Compagnie Lombard Odier SCmA’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-612
| Closed | -$84.4K | – | 440 |
|
|
2025
Q4 | $84.4K | Hold |
612
| – | – | ﹤0.01% | 307 |
|
|
2025
Q3 | $78.5K | Buy |
+612
| New | +$74.7K | ﹤0.01% | 321 |
|
|
2021
Q3 | – | Sell |
-300
| Closed | -$27K | – | 660 |
|
|
2021
Q2 | $27K | Hold |
300
| – | – | ﹤0.01% | 533 |
|
|
2021
Q1 | $26K | Hold |
300
| – | – | ﹤0.01% | 558 |
|
|
2020
Q4 | $28K | Buy |
+300
| New | +$26.2K | ﹤0.01% | 486 |
|
|
2020
Q1 | – | Sell |
-500
| Closed | -$44.6K | – | 544 |
|
|
2019
Q4 | $47K | Sell |
500
-15,700
| -97% | -$1.41M | ﹤0.01% | 361 |
|
|
2019
Q3 | $1.41M | Hold |
16,200
| – | – | 0.06% | 118 |
|
|
2019
Q2 | $1.48M | Sell |
16,200
-1,321
| -8% | -$112K | 0.06% | 123 |
|
|
2019
Q1 | $1.51M | Hold |
17,521
| – | – | 0.06% | 130 |
|
|
2018
Q4 | $1.35M | Hold |
17,521
| – | – | 0.06% | 139 |
|
|
2018
Q3 | $1.35M | Buy |
17,521
+17,075
| +3,828% | +$1.26M | 0.05% | 152 |
|
|
2018
Q2 | $30K | Sell |
446
-168
| -27% | -$11.6K | ﹤0.01% | 493 |
|
|
2018
Q1 | $44K | Sell |
614
-614
| -50% | -$46.7K | ﹤0.01% | 462 |
|
|
2017
Q4 | $94K | Buy |
1,228
+614
| +100% | +$46.3K | ﹤0.01% | 484 |
|
|
2017
Q3 | $47K | Sell |
614
-201
| -25% | -$15.2K | ﹤0.01% | 534 |
|
|
2017
Q2 | $61K | Sell |
815
-189
| -19% | -$13.4K | ﹤0.01% | 498 |
|
|
2017
Q1 | $67K | Sell |
1,004
-4,690
| -82% | -$313K | ﹤0.01% | 503 |
|
|
2016
Q4 | $371K | Buy |
5,694
+168
| +3% | +$10.9K | 0.01% | 365 |
|
|
2016
Q3 | $392K | Buy |
5,526
+2,432
| +79% | +$177K | 0.01% | 383 |
|
|
2016
Q2 | $228K | Sell |
3,094
-55
| -2% | -$3.8K | 0.01% | 459 |
|
|
2016
Q1 | $204K | Buy |
3,149
+2,767
| +724% | +$188K | 0.01% | 483 |
|
|
2015
Q4 | $29K | Sell |
382
-870
| -69% | -$69.1K | ﹤0.01% | 754 |
|
|
2015
Q3 | $103K | Buy |
1,252
+223
| +22% | +$19.8K | ﹤0.01% | 516 |
|
|
2015
Q2 | $91K | Buy |
1,029
+159
| +18% | +$14.6K | ﹤0.01% | 571 |
|
|
2015
Q1 | $77K | Hold |
870
| – | – | ﹤0.01% | 710 |
|
|
2014
Q4 | $72K | Hold |
870
| – | – | ﹤0.01% | 598 |
|
|
2014
Q3 | $73K | Hold |
870
| – | – | ﹤0.01% | 685 |
|
|
2014
Q2 | $71K | Sell |
870
-6,696
| -89% | -$527K | ﹤0.01% | 708 |
|
|
2014
Q1 | $576K | Sell |
7,566
-6,138
| -45% | -$447K | 0.02% | 295 |
|
|
2013
Q4 | $987K | Buy |
+13,704
| New | +$953K | 0.04% | 208 |
|
Other funds holding NVS
Compagnie Lombard Odier SCmA's NVS Position: Q1 2026 in Review
Compagnie Lombard Odier SCmA sold out of Novartis (NVS) in Q1 2026, closing a stake of 612 shares — an estimated $84.4K sold.
Compagnie Lombard Odier SCmA first reported a position in NVS in Q4 2013 and held it in 30 quarters. The position peaked at $1.51M in Q1 2019. 1,591 funds tracked by Wall St. Rank hold NVS as of Q1 2026.
- Compagnie Lombard Odier SCmA reported no remaining Novartis position as of Q1 2026 after selling out during the quarter.
- Compagnie Lombard Odier SCmA sold 612 Novartis shares in Q1 2026, an estimated $84.4K.
- Compagnie Lombard Odier SCmA first reported a position in Novartis in Q4 2013 and held it in 30 quarters.
- Compagnie Lombard Odier SCmA's Novartis position peaked at $1.51M in Q1 2019.
- 1,591 funds tracked by Wall St. Rank held Novartis as of Q1 2026.
Based on Compagnie Lombard Odier SCmA's 13F filing for Q1 2026, filed 15 Apr 2026.